Valeant Pharmaceuticals Intl Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Symbol: NYSE:VRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.45 billion
  • Outstanding Shares: 347,906,000
Average Prices:
  • 50 Day Moving Avg: $10.87
  • 200 Day Moving Avg: $13.53
  • 52 Week Range: $8.31 - $32.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.29
  • P/E Growth: -0.49
Sales & Book Value:
  • Annual Revenue: $9.41 billion
  • Price / Sales: 0.47
  • Book Value: $11.19 per share
  • Price / Book: 1.14
  • EBIDTA: $3.9 billion
  • Net Margins: -22.17%
  • Return on Equity: 43.81%
  • Return on Assets: 4.92%
  • Debt-to-Equity Ratio: 7.11%
  • Current Ratio: 1.46%
  • Quick Ratio: 1.12%
  • Average Volume: 25.14 million shs.
  • Beta: -0.17
  • Short Ratio: 1.73

Frequently Asked Questions for Valeant Pharmaceuticals Intl (NYSE:VRX)

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals Intl's earnings last quarter?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced its quarterly earnings results on Tuesday, May, 9th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.93. The firm earned $2.11 billion during the quarter, compared to analysts' expectations of $2.17 billion. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The company's revenue was down 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.08) EPS. View Valeant Pharmaceuticals Intl's Earnings History.

Where is Valeant Pharmaceuticals Intl's stock going? Where will Valeant Pharmaceuticals Intl's stock price be in 2017?

20 brokerages have issued 12 month price targets for Valeant Pharmaceuticals Intl's stock. Their predictions range from $8.00 to $105.00. On average, they anticipate Valeant Pharmaceuticals Intl's stock price to reach $22.74 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

What are analysts saying about Valeant Pharmaceuticals Intl stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals Intl stock:

  • 1. Royal Bank of Canada analysts commented, "We have revised our outlook due to the recent VRX financing and accounting treatment for Siliq revenues. While our revenue forecasts have increased due to Siliq, Adj. EBITDA forecasts have declined slightly. Following a modest increase in net debt, our price target declines to $18." (3/23/2017)
  • 2. Deutsche Bank AG analysts commented, "Lowered EPS on higher op ex, interest expense We updated our model following the company's 4Q results and 10-K filing, our meetings with management last week, and to reflect preliminary assumptions for the planned debt refinancing. Overall, we lowered our EPS estimates based primarily on higher spending and interest expense assumptions (see below), which reduced our DCF-derived PT to $19 (from $20). While our target implies material upside from the current stock price, we are sticking with our Hold rating pending greater visibility on improved demand trends for Xifaxan and other core assets, stabilization of the Dermatology business, and further steps to address the debt load and strengthen the balance sheet. We are encouraged that the company has begun to deliver on the expectations that it has set (as of 4Q), a theme we hope to see continue in the quarters ahead." (3/7/2017)
  • 3. Mizuho analysts commented, "The company is using its recently closed sale of assets to L'Oreal to repay $1.1B of a ~2.8% Term A loan due in 2018 (already excluded from our interest rate calculations). The company plans to refinance its existing credit agreement, issue new Term B loans that extend the maturity of current Term B loans due before 2022 (~$4.3B), issue new secured debt, and repay its remaining Term A loan due in April 2020 ($658M). Valeant also plans to repay a portion of its 6.75% secured debt due in 2018 (current balance is $1.59B). In tandem with this exercise, Valeant plans to relax its maintenance covenants in the revolver (currently $875M) and remove the covenants from its Term B loans. While the refinancing is not surprising, it reflects the cloudy outlook on future earnings, in our view." (3/6/2017)
  • 4. Jefferies Group LLC analysts commented, "Q4 EPS of $1.26 was ~5% ahead of cons with revs just topping guidance ($2.28-2.38B) at $2.40B. More importantly, FY17 EBITDA guidance (midpoint) was 6.5% below already lowered expectations, reflecting a decision to invest in hopes of a turnaround. Mgt noted that they have active processes underway for potential asset sales ' central to mgt's pledge of $5B in debt reduction by 2018. Divestitures remain critical to the co's NT share price outlook, in our view." (3/1/2017)
  • 5. BMO Capital Markets analysts commented, "VRX reported upside in 4Q with revenue of $2,403mn vs. BMO/consensus $2,351/2,339mn and EPS of $1.26 vs. BMO/consensus $1.25/1.21. The bigger focus was 2017 guidance where management struck a cautious tone given several moving parts, while expressing optimism on progress made and future growth potential with some core assets to help justify surprisingly robust spending levels. We're lowering our estimates meaningfully and our target goes to $19 from $21. We maintain our Market Perform; we remain cautious on VRX's outlook and ability to accelerate debt paydown, and await execution." (3/1/2017)

Are investors shorting Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl saw a increase in short interest in May. As of May 15th, there was short interest totalling 54,171,329 shares, an increase of 10.5% from the April 28th total of 49,024,853 shares. Based on an average trading volume of 43,109,236 shares, the short-interest ratio is presently 1.3 days. Approximately 16.0% of the shares of the company are sold short.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who owns Valeant Pharmaceuticals Intl stock?

Valeant Pharmaceuticals Intl's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (5.57%), VA PARTNERS I, LLC (5.20%), ValueAct Holdings L.P. (5.17%), Vanguard Group Inc. (2.01%), OppenheimerFunds Inc. (1.29%) and Morgan Stanley (0.80%). Company insiders that own Valeant Pharmaceuticals Intl stock include Anne Clem Whitaker, Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Pavel Mirovsky, Pershing Square Capital Manage, Robert L Rosiello, Ronald Harold Farmer, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals Intl.

Who sold Valeant Pharmaceuticals Intl stock? Who is selling Valeant Pharmaceuticals Intl stock?

Valeant Pharmaceuticals Intl's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Swiss National Bank, Mackenzie Financial Corp, Fosun International Ltd, Commerzbank Aktiengesellschaft FI, APG Asset Management N.V. and TD Asset Management Inc.. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

Who bought Valeant Pharmaceuticals Intl stock? Who is buying Valeant Pharmaceuticals Intl stock?

Valeant Pharmaceuticals Intl's stock was acquired by a variety of institutional investors in the last quarter, including ValueAct Holdings L.P., Saba Capital Management L.P., Bogle Investment Management L P DE, Morgan Stanley, OppenheimerFunds Inc., Vanguard Group Inc., Bank of Nova Scotia and KBC Group NV. Company insiders that have bought Valeant Pharmaceuticals Intl stock in the last two years include Anne Clem Whitaker, Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Robert L Rosiello, Ronald Harold Farmer, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Valeant Pharmaceuticals Intl stock cost?

One share of Valeant Pharmaceuticals Intl stock can currently be purchased for approximately $12.79.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:VRX) (?)
Ratings Breakdown: 2 Sell Ratings, 13 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $22.74 (77.77% upside)

Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:VRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017Barclays PLCReiterated RatingHold$20.00LowView Rating Details
5/19/2017Deutsche Bank AGSet Price TargetHold$18.00HighView Rating Details
5/19/2017Wells Fargo & CoReiterated RatingSell$8.00MediumView Rating Details
5/19/2017Rodman & RenshawReiterated RatingNeutral$17.00MediumView Rating Details
5/17/2017Stifel NicolausReiterated RatingBuy$45.00 -> $35.00LowView Rating Details
5/10/2017HC WainwrightSet Price TargetHold$17.00LowView Rating Details
5/10/2017BMO Capital MarketsReiterated RatingMarket PerformHighView Rating Details
5/10/2017ScotiabankBoost Price TargetSector Perform$12.00 -> $14.00HighView Rating Details
5/10/2017TD SecuritiesLower Price TargetHold$18.50 -> $15.00HighView Rating Details
5/10/2017BTIG ResearchReiterated RatingNeutralMediumView Rating Details
5/10/2017Royal Bank of CanadaReiterated RatingSector Perform -> Sector Perform$18.00 -> $19.00HighView Rating Details
5/8/2017Canaccord GenuitySet Price TargetHold$12.00HighView Rating Details
5/9/2017JPMorgan Chase & Co.Reiterated RatingHoldMediumView Rating Details
5/6/2017Jefferies Group LLCSet Price TargetBuy$18.00HighView Rating Details
4/17/2017MizuhoReiterated RatingUnderperform$9.00 -> $8.00LowView Rating Details
4/14/2017Piper Jaffray CompaniesReiterated RatingOutperform$10.00N/AView Rating Details
3/11/2017Morgan StanleyReiterated RatingEqual Weight$17.00 -> $12.00N/AView Rating Details
2/28/2017GuggenheimReiterated RatingBuy$55.00N/AView Rating Details
5/29/2016Susquehanna Bancshares IncReiterated RatingHold$105.00N/AView Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/1/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00N/AView Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00N/AView Rating Details
12/21/2015Bank of America CorpReiterated RatingBuyN/AView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldN/AView Rating Details
11/2/2015Goldman Sachs Group IncDowngradeBuy -> Neutral$180.00 -> $122.00N/AView Rating Details
10/23/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformN/AView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyN/AView Rating Details
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00N/AView Rating Details
7/10/2015Howard WeilInitiated CoverageOutperform$290.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Valeant Pharmaceuticals Intl (NYSE:VRX)
Earnings by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)
Earnings History by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017$0.87$2.80$2.17 billion$2.11 billionViewListenView Earnings Details
2/28/2017Q416$1.20$1.26$2.34 billion$2.40 billionViewListenView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Valeant Pharmaceuticals Intl (NYSE:VRX)
2017 EPS Consensus Estimate: $3.87
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.94$0.94$0.94
Q2 20171$1.01$1.01$1.01
Q3 20171$0.94$0.94$0.94
Q4 20171$0.98$0.98$0.98
(Data provided by Zacks Investment Research)


Dividend History for Valeant Pharmaceuticals Intl (NYSE:VRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals Intl (NYSE:VRX)
Insider Ownership Percentage: 16.37%
Institutional Ownership Percentage: 64.34%
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)
Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Schutter Richard U DeDirectorBuy20,000$13.90$278,000.00View SEC Filing  
3/15/2017Schutter Richard U DeDirectorBuy10,000$10.80$108,000.00View SEC Filing  
3/14/2017Paul HerendeenCFOBuy24,000$10.72$257,280.00View SEC Filing  
3/14/2017Valueact Capital Master Fund,InsiderBuy3,000,000$10.82$32,460,000.00View SEC Filing  
3/13/2017Pershing Square Capital ManageDirectorSell18,114,432$11.00$199,258,752.00View SEC Filing  
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.00View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Valeant Pharmaceuticals Intl (NYSE:VRX)
Latest Headlines for Valeant Pharmaceuticals Intl (NYSE:VRX)
DateHeadline logoValeant Pharmaceuticals Intl Inc (VRX) Upgraded to Strong-Buy by Vetr Inc. - May 25 at 12:38 AM logoValeant: A Valuation Check - Seeking Alpha - May 23 at 7:59 PM logoTake Profits Now in Valeant Pharmaceuticals Intl Inc (VRX) Stock - - May 23 at 7:59 PM logoTake Profits Now in Valeant Pharmaceuticals Intl Inc (VRX) Stock - May 23 at 1:55 PM logoValeant Pharmaceuticals Intl Inc (VRX) Lowered to Buy at Vetr Inc. - May 23 at 12:38 AM logoBausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution - May 22 at 8:13 AM logoValeant Pharmaceuticals Intl Inc (VRX) Receives Neutral Rating from Rodman & Renshaw - May 19 at 10:18 PM logoValeant Pharmaceuticals Intl Inc (VRX) Earns "Sell" Rating from Wells Fargo & Co - May 19 at 8:29 PM logoValeant Pharmaceuticals Intl Inc (VRX) Given a $18.00 Price Target at Deutsche Bank AG - May 19 at 7:45 PM logoIt's the Truth: Valeant Pharmaceuticals' Debt Situation Is Worse Now Than a Year Ago - May 19 at 6:40 PM logoSALT Spotlight: Ackman Explains His Valeant 'Mistake' - May 19 at 6:40 PM logoBill Ackman has ‘something to prove’ after Valeant mistake - May 19 at 6:40 PM logoValeant's Revenue Growth Is At Risk - Valeant Pharmaceuticals ... - Seeking Alpha - May 18 at 10:13 AM logoValeant Pharmaceuticals Intl Inc (VRX) Earns "Buy" Rating from Stifel Nicolaus - May 17 at 1:32 PM logoStatement Regarding Xifaxan Intellectual Property Litigation - May 17 at 8:49 AM logoValeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan - May 17 at 8:49 AM logoWhy Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Still Ugly As Ever - May 16 at 11:46 AM logo[$$] ValueAct’s Jeffrey Ubben Hands Reins to Protégé Mason Morfit - May 16 at 8:17 AM logoValeant Pharmaceuticals: Why One Bear is Staying Bearish - May 15 at 7:44 PM logo[$$] Ubben steps down as investment head at ValueAct - May 15 at 7:44 PM logoETFs with exposure to Valeant Pharmaceuticals International, Inc. : May 15, 2017 - May 15 at 7:44 PM logoSchutter Richard U. De Acquires 20,000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock - May 15 at 7:30 PM logoIs This the Real Reason Valeant's Shares Are Skyrocketing? - May 14 at 11:58 AM logoValeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 14 at 11:58 AM logoValeant Pharmaceuticals: Living to Fight Another Day? - May 14 at 11:58 AM logoHC Wainwright Analysts Give Valeant Pharmaceuticals Intl Inc (VRX) a $17.00 Price Target - May 13 at 5:14 PM logoValeant: 6 Months Later - Seeking Alpha - May 12 at 3:29 PM logoValeant: More Debt Than Enterprise Value - Seeking Alpha - May 12 at 3:29 PM logoGo Long Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free - - May 12 at 3:29 PM logoValeant Pharmaceuticals International, Inc. – Value Analysis (NYSE:VRX) : May 11, 2017 - May 12 at 4:14 AM logoGo Long Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free - May 11 at 1:33 PM logoValeant Pharmaceuticals: The End of the Beginning? - May 11 at 3:18 AM logoValeant Expresses Confidence In Outlook, But Might Be Too Early To Get Bullish - May 11 at 3:18 AM logoValeant Pharmaceuticals Intl Inc (VRX) Given "Equal Weight" Rating at Barclays PLC - May 10 at 10:02 PM logoValeant Pharmaceuticals Intl's (VRX) "Buy" Rating Reiterated at Stifel Nicolaus - May 10 at 10:02 PM logoValeant Pharmaceuticals Intl Inc (VRX) Receives Neutral Rating from BTIG Research - May 10 at 10:02 PM logoValeant Pharmaceuticals Intl Inc (VRX) Earns "Market Perform" Rating from BMO Capital Markets - May 10 at 7:36 PM logoValeant Pharmaceuticals Intl Inc (VRX) PT Raised to $14.00 at Scotiabank - May 10 at 2:10 PM logoValeant Pharmaceuticals Intl Inc (VRX) Price Target Cut to $15.00 by Analysts at TD Securities - May 10 at 2:10 PM logoValeant Pharmaceuticals Intl Inc (VRX) Announces Quarterly Earnings Results, Beats Estimates By $1.93 EPS - May 10 at 12:53 PM logoValeant: Huge Legal Risk - Seeking Alpha - May 10 at 9:54 AM logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is Still Hot Garbage - - May 10 at 9:54 AM logoToday's Research Reports on Stocks to Watch: Endo International and Valeant Pharmaceuticals - May 10 at 9:54 AM logoValeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bullish Manner : VRX-US : May 10, 2017 - May 10 at 9:54 AM logoValeant Pharmaceuticals' Q1 Report Might Be the Greatest Smoke-and-Mirrors Show You'll Ever See - May 10 at 9:54 AM logoInvestors Purchase High Volume of Valeant Pharmaceuticals Intl Call Options (VRX) - May 10 at 7:08 AM logoJPMorgan Chase & Co. Reaffirms Hold Rating for Valeant Pharmaceuticals Intl Inc (VRX) - May 9 at 11:36 PM logoValeant: Is That All? - May 9 at 8:03 PM logoWhy Valeant Pharmaceuticals Stock Is Soaring Today - May 9 at 8:03 PM logoCANADA STOCKS-TSX dragged by banks and energy; Valeant, Home Capital surges - May 9 at 8:03 PM



Valeant Pharmaceuticals Intl (VRX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff